It is noteworthy that out of the seven upregulated DEGs, expression of SPINK9 (Serine protease inhibitor Kazal type 9) and MYO3A (Myosin IIIA) were increased significantly in all T1DM complications compared to TIDM without complication and this highlights an important observation and introduces these two candidate genes as potential biomarkers for developing single or multiple complications in T1DM. The gene discussed is MYO3A; the disease is type 1 diabetes mellitus.